STOCK TITAN

If You Invested in Pasithea Therapeutics Corp. (KTTA)

Healthcare · Biotechnology · NASDAQ
Looking for the current price? See the KTTA quote & overview
$1,000 invested 1 Year Ago
$1,127
+12.7% price return
+12.7% with dividends reinvested
Bought on Nov 24, 2025 at $0.4248 split-adjusted
$1,000 invested 5 Years Ago
$11
-98.9% price return -59.6% CAGR
-98.9% with dividends reinvested
Bought on Nov 22, 2021 at $44.20 split-adjusted
$1,000 invested 10 Years Ago
N/A
Our prices start Sep 15, 2021

What $1,000 or $10,000 in KTTA Would Be Worth Now

Real historical value by amount invested and how long ago
If you invested 1 year ago 5 years ago 10 years ago Since Sep 15, 2021
$1,000 $1,127 +13% $11 -99% — $6.72 -99%
$10,000 $11,269 +13% $108 -99% — $67 -99%

Based on real historical closing prices adjusted for stock splits, without dividends, through 2026-11-20. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.

Custom Calculation

Choose your own date and amount for KTTA

$1,000 Investment Over Time

KTTA vs S&P 500

Year-by-Year Returns

KTTA annual performance
Year Start Price End Price Annual Return Cumulative
2021Sep 15 to Dec 31 $71.20 $35.40 -50.3% -50.3%
2022 $35.40 $12.83 -63.7% -82.0%
2023 $12.83 $7.40 -42.3% -89.6%
2024 $7.40 $3.15 -57.4% -95.6%
2025 $3.15 $1.29 -59.0% -98.2%
2026Dec 31, 2025 to Nov 20 $1.29 $0.4787 -62.9% -99.3%

About Pasithea Therapeutics Corp.

Healthcare · NASDAQ

Pasithea Therapeutics Corp. is a clinical-stage biotechnology company developing drug candidates for central nervous system disorders, RASopathies, MAPK pathway-driven tumors and other diseases. The company’s common stock trades on The Nasdaq Capital Market under the symbol KTTA, and its listed warrants trade under KTTAW. Pasithea is organized as a Delaware corporation and reports its principal executive office in Miami Beach, Florida.

The company’s current development focus is PAS-004, a next-generation macrocyclic MEK inhibitor. MEK inhibition targets signaling in the MAPK pathway, a biology area relevant to RASopathies and certain tumors. Pasithea describes PAS-004 as its lead therapeutic candidate and has positioned the program for neurofibromatosis type 1, including NF1-associated plexiform neurofibromas and cutaneous neurofibromas, as well as MAPK pathway-driven tumors and other diseases.

Lead program and disease focus

Pasithea’s PAS-004 program is centered on diseases where aberrant MAPK pathway signaling is a therapeutic target. The company has identified neurofibromatosis type 1, or NF1, as a principal indication area, with clinical development directed at NF1-associated plexiform neurofibromas and related manifestations. The company has also reported clinical development activity in advanced cancer and research activity related to amyotrophic lateral sclerosis, or ALS.

PAS-004 has received U.S. Food and Drug Administration regulatory designations for specific NF1 uses, including Orphan Drug Designation, Fast Track Designation and Rare Pediatric Disease Designation. These designations are part of the regulatory framework for developing therapies for serious, rare or pediatric diseases and are distinct from product approval. Pasithea remains a development-stage company, and its business model depends on research, clinical development, regulatory progress, financing activity and potential future commercialization or licensing outcomes.

Business model and operating structure

Pasithea operates as a biotechnology research and development company rather than as a commercial drug seller. Its recurring activities include preclinical research, clinical trial execution, regulatory communications, medical strategy, intellectual property development, financing transactions and corporate governance. The company’s reported business is focused on research and development of treatments for central nervous system disorders and other diseases, including RASopathies and certain cancers.

Like many clinical-stage biotechnology issuers, Pasithea funds its operations through capital markets activity and other financing sources while advancing its product candidates through clinical and regulatory pathways. Company disclosures also reference potential use of capital for ongoing research, clinical trials, development of biological and pharmaceutical technologies, licensing activities, acquisitions of complementary technologies or businesses and working capital.

Public-company profile

Pasithea is an emerging growth company under U.S. securities rules, according to its SEC filings. Its public-company disclosures cover its common stock and warrants, registration statements for securities offerings, governance matters, equity incentive plan approvals, executive appointments, Regulation FD communications, Nasdaq listing compliance matters, and risk factors associated with a clinical-stage biotechnology company. These disclosures frame Pasithea as a focused drug-development issuer whose value proposition is tied primarily to PAS-004 and related clinical, regulatory and financing developments.

Market Cap
$17.6M
Current Price
$0.4787
EPS (FY2025)
-$2.91
View full KTTA overview

Frequently Asked Questions

Pasithea Therapeutics Corp. investment returns

How much would $1,000 invested in Pasithea Therapeutics Corp. be worth today?

If you invested $1,000 in Pasithea Therapeutics Corp. (KTTA) 5 years ago on 2021-11-22, your investment would be worth $11 as of 2026-11-20, a -98.9% price return without dividends, growing at a compounded rate of -59.6% per year (CAGR).

Has Pasithea Therapeutics Corp. outperformed the S&P 500?

Comparison data requires at least 10 years of trading history. Use the calculator above to compare KTTA performance over available time periods.

What is Pasithea Therapeutics Corp.'s average annual return?

The compound annual growth rate (CAGR) of KTTA’s share price over the past 5 years is -59.6%, without dividends. Individual years vary a great deal, and KTTA’s best recent full year was 2023 (-42.3%) while the worst was 2022 (-63.7%).

For informational and educational purposes only, not investment advice.